 Mylan N.V. said Thursday it had net income of 39.4 million, or 8 cents a share, in the second quarter, after a loss of 168.5 million, or 33 cents a share, in the year-earlier period. The company said its adjusted net income came to 574.3 million compared with 532.8 million a year ago, but did not offer an adjusted per-share figure. Revenue fell to 2.731 billion from 2.852 billion. The FactSet consensus was for EPS of 99 cents and revenue of 2.735 billion. We now expect the overall COVID-19 recovery efforts will occur slower than anticipated and may continue throughout the rest of the year, the company said in a statement. As a result, we expect total revenues, which absorbed a 2 net decline related to COVID-19 in the first half of the year, to have an overall similar negative impact for the second half of the year. Mylan now expects full-year revenue to range from 11.5 to 12.0 billion. The company is expecting the acquisition of Pfizers Upjohn business to be completed in the fourth quarter. Shares were slightly higher premarket, but have fallen 16 in the year to date, while the SP 500 has gained 3. 